Safety and efficacy of CPX-351 in younger patients (&amp;lt;60 years old) with secondary acute myeloid leukemia
Authors: Amanda Przespolewski, Aaron D. Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang
Journal: Blood (2022)

Letter to Blood| March 23, 2023 Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia Clinical Trials & Observations Amanda Przespolewski, Amanda Przespolewski Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY https://orcid.org/0000-0002-8241-8288 Search for other works by this author on: This Site PubMed Google Scholar Aaron D. Goldberg, Aaron D. Goldberg Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY https://orcid.org/0000-0002-2892-2643 Search for other works by this author on: This Site PubMed Google Scholar Chetasi Talati, Chetasi Talati Moffitt Cancer Center, Tampa, FLAbbVie Inc, North Chicago, IL Search for other works by this author on: This Site PubMed Google Scholar Salman Fazal, Salman Fazal Allegheny Health Network, Pittsburgh, PA Search for other works by this author on: This Site PubMed Google Scholar Pankit Vachhani, Pankit Vachhani O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL https://orcid.org/0000-0001-9779-6217 Search for other works by this author on: This Site PubMed Google Scholar Srinivasa R. Sanikommu, Srinivasa R. Sanikommu Levine Cancer Institute, Charlotte, NC Search for other works by this author on: This Site PubMed Google Scholar Swapna Thota, Swapna Thota Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NYThe University of Tennessee Health Science Center, Memphis, TN https://orcid.org/0000-0002-4216-1414 Search for other works by this author on: This Site PubMed Google Scholar Julian Waksal, Julian Waksal Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NYDepartment of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY https://orcid.org/0000-0001-6167-4322 Search for other works by this author on: This Site PubMed Google Scholar Brian Ball, Brian Ball Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NYDepartment of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope Cancer Center, Duarte, CA Search for other works by this author on: This Site PubMed Google Scholar Christopher Famulare, Christopher Famulare Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY Search for other works by this author on: This Site PubMed Google Scholar Maximilian Stahl, Maximilian Stahl Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NYDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA Search for other works by this author on: This Site PubMed Google Scholar Jeffrey Baron, Jeffrey Baron Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY https://orcid.org/0000-0002-9985-3403 Search for other works by this author on: This Site PubMed Google Scholar Elizabeth A. Griffiths, Elizabeth A. Griffiths Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY https://orcid.org/0000-0002-0288-8248 Search for other works by this author on: This Site PubMed Google Scholar James E. Thompson, James E. Thompson Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY https://orcid.org/0000-0003-3030-7559 Search for other works by this author on: This Site PubMed Google Scholar Kendra Sweet, Kendra Sweet Moffitt Cancer Center, Tampa, FL Search for other works by this author on: This Site PubMed Google Scholar Eunice S. Wang Eunice S. Wang Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY Search for other works by this author on: This Site PubMed Google Scholar Blood (2023) 141 (12): 1489–1493. https://doi.org/10.1182/blood.2022016678 Article history Submitted: April 13, 2022 Accepted: November 23, 2022 Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Request Permissions Cite Icon Cite Search Site Citation Amanda Przespolewski, Aaron D. Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang; Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia. Blood 2023; 141 (12): 1489–1493. doi: https://doi.org/10.1182/blood.2022016678 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsBlood Search Subjects: Clinical Trials and Observations, Myeloid Neoplasia TO THE EDITOR: Patients with secondary acute myeloid leukemia (s-AML), a category which includes AML with myelodysplasia-related changes (AML-MRC) and treatment-related AML (t-AML), have poor long-term outcomes following standard induction chemotherapy ("7+3").1,2 A previous population-based study demonstrated median survival of 6 to 7 months for patients with s-AML and 8 to 14 months for those with t-AML.1 In 2017, a liposomal cytarabine and daunorubicin formulation (CPX-351) was Food and Drug Administration (FDA) approved for upfront treatment of s-AML based on a pivotal phase 3 trial demonstrating improved overall survival (OS) (9.56 vs 5.95 months; hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.52-0.9) and remission rates (complete remission [CR]/CR with incomplete count recovery [CRi]) (47.7% vs 33.3%; P = .016) in patients aged 60 to 75 years old than induction chemotherapy with "7+3."3 The benefits from... References 1.Hulegardh E, Nilsson C, Lazarevic V, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90(3):208-214.Google ScholarCrossrefSearch ADS PubMed 2.Martinez-Cuadron D, Megias-Vericat JE, Serrano J, et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022;6(4):1278-1295.Google ScholarCrossrefSearch ADS PubMed 3.Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684-2692.Google ScholarCrossrefSearch ADS 4.Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8(7):e481-e491.Google ScholarCrossrefSearch ADS PubMed 5.Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642-4649.Google ScholarCrossrefSearch ADS 6.Benitez LL, Perissinotti AJ, Rausch CR, et al. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leuk Lymphoma. 2021;62(9):2184-2192.Google ScholarCrossrefSearch ADS PubMed 7.Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010;28(3):405-411.Google ScholarCrossrefSearch ADS 8.Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010;115(9):1850-1857.Google ScholarCrossrefSearch ADS PubMed 9.Nilsson C, Hulegardh E, Garelius H, et al. Secondary acute myeloid leukemia and the role of allogeneic stem cell transplantation in a population-based setting. Biol Blood Marrow Transplant. 2019;25(9):1770-1778.Google ScholarCrossrefSearch ADS PubMed 10.Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol. 2000;18(5):963-971.Google ScholarCrossrefSearch ADS 11.Matthews A, Perl AE, Luger SM, et al. Real-world effectiveness of CPX-351 vs. venetoclax and azacitadine for in acute myeloid leukemia. Blood Adv. 2022;6(13):3997-4005.Google ScholarCrossrefSearch ADS PubMed © 2023 by The American Society of Hematology2023 © 2023 by The American Society of Hematology2023 You do not currently have access to this content. Sign in via your Institution